SOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Senti Bio’s Co-Founder and Chief Executive Officer of Senti, participated in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference. As part of the event, Dr. Lu dove deeper into his dedicat ...

Core Insights - Senti Bio is presenting its innovative logic-gated CAR-NK cell therapy, which targets leukemic cells while preserving healthy bone marrow [1] - The presentation will take place at the BioScience Forum on July 23, 2025, featuring Dr. Kanya Rajangam as the speaker [2] Company Overview - Senti Bio is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][4] - The company aims to create therapies that can precisely kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing control post-administration [4] - Senti Bio's pipeline includes cell therapies engineered with Gene Circuits targeting both liquid and solid tumors, with preclinical evidence supporting their efficacy in NK and T cells [4]

Core Insights - Senti Biosciences, Inc. has appointed Bryan Baum to its Board of Directors, enhancing its leadership team with his extensive entrepreneurial and investment experience [1][3][4] - Bryan Baum is recognized for his successful track record in scaling companies and has invested in notable firms such as SpaceX, OpenAI, and Airbnb, which may provide strategic advantages to Senti Bio [2][3] - The company is focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, aiming to address cancer treatments that current drugs cannot [3][5] Company Overview - Senti Bio is a clinical-stage biotechnology company that leverages synthetic biology to engineer Gene Circuits for new medicines, targeting incurable diseases [5] - The company's pipeline includes cell therapies designed to specifically target and kill cancer cells while sparing healthy cells, with preclinical evidence supporting their efficacy in both NK and T cells [5] - Senti Bio is also exploring the potential of Gene Circuits in other disease modalities beyond oncology, indicating a broad scope for future development [5]

SENTI-202 Program Highlights - SENTI-202 is a first-in-class off-the-shelf Logic-Gated selective CD33 OR FLT3 NOT EMCN CAR NK cell therapy targeting AML [4, 5, 52] - The therapy is designed to selectively kill both AML blasts and LSCs while protecting healthy HSPCs [15, 52] - Preliminary Phase 1 trial data shows positive efficacy in R/R AML [5] Clinical Trial & Patient Data - The Phase 1 trial (SENTI-202-101) enrolled heavily pretreated R/R AML patients with poor prognosis [18, 52] - The study identified a preliminary Recommended Phase 2 Dose (RP2D) [20, 22, 52] - The opening dose cohort was anticipated to be biologically active [18, 22] - The median time from AML diagnosis to trial entry was less than 1 year [25] - Patients had received a median of 2 prior lines of therapy [27] Safety & Tolerability - SENTI-202 was generally well-tolerated in R/R AML patients [30, 52] - Most frequent Grade 3+ AEs were hematologic and consistent with R/R AML patients receiving lymphodepletion [29, 52] - The Maximum Tolerated Dose (MTD) was not reached, and the preliminary RP2D was identified as 1.5 x 10^9 cells/dose x 3 weekly doses/28 days [52] Efficacy & Response - Across all patients, the Overall Response Rate (ORR) was 71% (5/7) and the composite Complete Remission (cCR) rate was 57% (4/7) [33, 57] - In the preliminary RP2D cohort, the cCR rate was 67% (2/3) [33, 57] - All cCR patients (4/4) achieved MRD- status as assessed per local standard of care [33, 57] - All cCR patients maintained morphologic remission with the longest follow-up of 8+ months [57]

Core Insights - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [2][3] - The company's lead program, SENTI-202, is a first-in-class CAR NK cell therapy targeting hematologic malignancies, currently in a Phase 1 clinical trial with positive preliminary data [3] - SENTI-202 has received Orphan Drug Designation from the FDA for treating relapsed/refractory hematologic malignancies, including AML [3] Company Overview - Senti Bio aims to create new medicines for patients with incurable diseases by engineering Gene Circuits that can precisely target and kill cancer cells while sparing healthy cells [5] - The company's pipeline includes cell therapies designed to address challenging liquid and solid tumor indications, with Gene Circuits shown to work in both NK and T cells [5] - Senti Bio is also exploring the application of Gene Circuits in other diseases beyond oncology through partnerships [5]

Core Insights - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][3] - The company will present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference, highlighting its innovative approach to tumor-specific therapies [1] Company Overview - Senti Bio is dedicated to creating new cell and gene therapies for patients with incurable diseases, utilizing synthetic biology to engineer Gene Circuits for enhanced precision and control [3] - The company's pipeline includes cell therapies designed to target both liquid and solid tumors, with preclinical evidence supporting the efficacy of Gene Circuits in NK and T cells [3] Conference Details - The SEED Conference, established in 2014, serves as a premier event for synthetic biologists, facilitating networking and collaboration among over 5,000 professionals in the field [1] - Senti Bio's presentation will focus on "Solving the Grand Challenge of Tumor-Specific Therapies with Logic-Gated Cells," showcasing its advancements in the field [1]

Core Insights - Senti Biosciences, Inc. announced progress in the Phase 1 clinical trial of SENTI-202 for treating Acute Myeloid Leukemia (AML), with the FDA granting Orphan Drug Designation for the therapy [1][2] - The company aims to address the significant unmet need in relapsed/refractory AML, which has a median survival rate of only 5.3 months [2] - SENTI-202 is designed to selectively target and eliminate CD33 and/or FLT3-expressing hematologic malignancies while sparing healthy cells [2] Company Overview - Senti Bio is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][4] - The company’s pipeline includes cell therapies engineered with Gene Circuits targeting challenging liquid and solid tumor indications [4] - Senti Bio's Gene Circuits have shown preclinical efficacy in both NK and T cells, with potential applications beyond oncology [4] Regulatory Milestone - The FDA's Orphan Drug Designation provides Senti Bio with various benefits, including tax credits and exemptions from certain FDA fees, as well as potential market exclusivity for seven years post-approval [3]

Core Insights - Senti Biosciences, Inc. is participating in a Virtual Fireside Chat hosted by Chardan Capital Markets on June 9, 2025, featuring key executives discussing the company's advancements in biotechnology [1][2]. Company Overview - Senti Biosciences is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][3]. - The company aims to create therapies that can precisely target and kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing for controllability post-administration [3]. - Senti's pipeline includes cell therapies engineered with Gene Circuits targeting both liquid and solid tumors, with preclinical evidence supporting their efficacy in NK and T cells [3]. Additional Information - For further details, Senti Biosciences encourages stakeholders to visit their official website and follow their social media channels for updates and disclosures [4].

Summary of Scenti Biosciences Conference Call Company Overview - **Company**: Scenti Biosciences - **Industry**: Biotechnology - **Focus**: Development of cell and gene therapies for incurable diseases using a synthetic biology platform called GeneCircuits [1][2] Core Technology and Product Development - **Technology**: Logic gating technology allows targeting of previously untreatable cancers, enhancing precision and control in therapy [3][4] - **Lead Program**: Santi 202, targeting relapsed/refractory Acute Myeloid Leukemia (AML) and related cancers, currently in early-stage clinical trials [4][5] - **Manufacturing**: Scalable off-the-shelf manufacturing streamlines treatment for patients [5] Clinical Data and Efficacy - **Clinical Results**: Positive data reported at AACR 2025 meeting, with five patients achieving overall response rate (ORR) and four achieving complete response [15] - **Durability**: Longest-term patient response lasted over eight months, indicating potential for outpatient use [14][15] - **Patient Population**: AML affects over 20,000 newly diagnosed patients annually, with a 60% relapse rate within 12 months [10] Mechanism of Action - **Logic Gates**: Designed to differentiate between cancerous and healthy cells, minimizing toxicity [7][8] - **Cell Engineering**: Utilizes natural killer (NK) cells genetically modified to express proteins targeting AML cells while protecting healthy cells [11][12] - **Key Proteins**: Includes activating CAR (ACAR) targeting CD33 and FLT3, and an inhibitory CAR that protects healthy cells [12][13] Clinical Trial Design - **Phase One Trial**: Multicenter, multinational study assessing two dose levels (1 billion and 1.5 billion CAR positive NK cells) [16][17] - **Dosing Schedule**: Patients receive multiple doses, with assessments for response at 28 days [18] Safety and Tolerability - **Patient Monitoring**: Recovery of healthy blood cell counts observed post-treatment, indicating maintenance of healthy bone marrow [22][23] - **Toxicity Management**: Logic gating technology aims to reduce toxicity associated with traditional therapies [7][8] Future Directions - **Expansion Plans**: Focus on increasing patient numbers and showcasing the efficacy of logic gating technology [30][31] - **Broader Applications**: Potential to apply logic gating technology to solid tumors and other cancer types [25][28] Competitive Landscape - **Differentiation**: Scenti's approach is agnostic to genetic mutations, providing a complementary mechanism to existing therapies targeting genetic mutations in AML [32] - **Comparison with CAR T**: NK cells are preferred for AML due to their rapid action and safety profile, while T cells may be more suitable for solid tumors [33][34] Conclusion - **Outlook**: Scenti Biosciences is positioned to advance its lead program Santi 202 and explore broader applications of its technology in the oncology space, with ongoing clinical trials and promising early results [27][28]

Company Overview - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [3] - The company aims to create new medicines that can precisely target and kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing for control even after administration [3] Upcoming Event - Timothy Lu, M.D., Ph.D., Co-Founder and CEO of Senti Bio, will present at the LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on May 29, 2025, at 2:40 PM ET [1][2] Technology and Pipeline - Senti Bio's pipeline includes cell therapies engineered with Gene Circuits targeting challenging liquid and solid tumor indications [3] - The Gene Circuits have shown preclinical efficacy in both NK and T cells, with potential applications extending beyond oncology [3]